Status of soluble ST2 levels in serum of HTLV-1 infected individuals by Avval, Farnaz Zahedi et al.
Acta Microbiologica et Immunologica Hungarica, 62 (2), pp. 137–145 (2015)
DOI: 10.1556/030.62.2015.2.4
1217-8950/$20.00 © 2015 Akadémiai Kiadó, Budapest
STATUS OF SOLUBLE ST2 LEVELS IN SERUM 
OF HTLV-1 INFECTED INDIVIDUALS
FARNAZ ZAHEDI AVVAL1, SHADI SHOMALI1, MOHAMMAD NADRI1, 
REZA BOOSTANI2, 3, LIDA JARAHI4 and MASOUD YOUSSEFI5, 6*
1Department of Biochemistry, School of Medicine, 
Mashhad University of Medical Sciences, Mashhad, Iran
2Department of Neurology, Ghaem Hospital, School of Medicine, 
Mashhad University of Medical Sciences, Mashhad, Iran
3HTLV-1 and Associated Diseases Research Center, Ghaem Hospital, 
Mashhad University of Medical Sciences, Mashhad, Iran
4Addiction Research Center, Faculty of Medicine, 
Mashhad University of Medical Sciences, Mashhad, Iran
5Department of Microbiology and Virology, School of Medicine, 
Mashhad University of Medical Science, Mashhad, Iran
6Antimicrobial Resistance Research Center, Bu-Ali Research Institute, 
Mashhad University of Medical Science, Mashhad, Iran
(Received: 29 September 2014; Accepted: 12 February 2015)
ST2 is a member of IL-1 receptor family expressed on Th2 cells and regulates 
Th2 responces. The gene of ST2 encodes soluble ST2 (sST2) and the transmembrane 
ST2 (ST2L) isoforms through alternative mRNA splicing. The discovery of IL33/
ST2 signaling pathway, has drawn a great scientifi c attention to this system. sST2 
has been shown to be an indacating factor in various infl ammatory conditions. This 
study aims to evaluate serum sST2 levels in HTLV-1 infected patients. This study 
included 49 HTLV-1 seropositive cases of which 14 were sympthomatic. Controls 
consisted of 30 healthy volunteers. sST2 level was measured using a quantitative 
ELISA assay and the results of the study groups were compared. Corroborating the 
previous reports, sST2 was lower in females (P = 0.003). The sST2 levels was slight-
ly increased in HTLV-1 patients, though such increase was not statistically signifi -
cant (P = 0.91), in addition sST2 level did not correlate signifi cantly to the disease 
duration (P = 0.78). Despite some other chronic viral infection, HTLV-1 seems not to 
induce high serum sST2. However owing to relatively high normal variation of sST2 
levels and rather small sample size, we stongly recommend further reseach with 
preferably larger sample size to evalute sST2 in HTLV-1 infected patients.
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Introduction
The human T-lymphotropic virus type 1 (HTLV-1), one of the fi rst known 
human retroviruses affecting 10 to 20 millions people worldwide. HTLV-1 
spreads globally and is endemic in Africa, south America, north east of Iran and 
in some regions of Japan [1]. In about one person out of 20, symptomatic diseases 
associated with HTLV-1 occurs; among these diseases, adult T-cell leukemia/
lymphoma (ATLL) and HTLV-1 associated myelopathy/tropical spastic parapare-
sis (HAM/TSP) are clinically more signifi cant [2, 3]. HAM/TSP a spastic para-
plegia has been confi rmed to be mainly due to the infl ammatory responses in 
spinal cord [2]. Cytokines are thought to play an important role in neurodegen-
eration occurring in spinal cord of HAM/TSP patients [4]. High levels of tumor 
necrosis factor alfa (TNFα) and a number of cytokines such as interleukine-1 β 
(IL-1β), IL-1α and IL-6 have been observed in these patients [5–7].
ST2, also known as IL-1 R4, is a member of the interleukin-1 receptor 
 (IL-1 R) family. ST2 gene encodes two distinict forms of receptors: a long mem-
brane-anchored form (ST2L), which is expressed on mast cells [8], macrophages 
[9] and T helper type 2 but not Th1 cells [10], and a soluble form (sST2) which is 
produced through different splicing of the gene [11].
ST2L which is mainly expressed on activated Th2 cells is thought to medi-
ate Th2 effector functions through IL33/ST2 signalling pathway [10]. IL-33 a 
cytokine belonging to the IL-1 family which plays a critical role in Th2 immune 
responses, binds to its receptor ST2L and stimulates the target cells [12, 13]. 
 IL-33 is a multifunctional immunomodulatory cytokine that acts both pro- and 
anti-infl ammatory depending on the disease state or in vitro experimental con-
ditions [14, 15]. The soluble form of ST2 (sST2) is secreted to the serum and 
acts as a decoy, negative regulatory receptor, namely binds to the free IL-33 and 
prevents the IL33/ST2L signaling function. Studies have revealed that stimula-
tion with lipopolysaccharide (LPS), IL-1b, TNF-a and IL-6 induce the production 
of sST2 [16, 17]. Also, in murine models induction of sST2 expression has been 
demonstrated by pro-infl ammatory stimuli [9, 18].
Elevated serum levels of sST2, have been reported in a wide range of dis-
eases such as autoimmune diseases [19], asthma [20], sepsis and LPS induced 
infl ammations [21], as well as chronic viral infections such as HIV-1 [22]. 
We  hypothesized that due to the Th2 responses during HTLV-1 infection [23], the 
sST2 might serve as a marker of progression and severity of the disease in par-
ticular in HAM/TSP patients, therefore the sST2 levels in HTLV-1 positive indi-
viduals including HAM/TSP patients were studied and compared with healthy 
controls.
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Methods
Study groups
A total of 49 HTLV-1 positive cases and 30 healthy individuals partici-
pated the study. The mean age±SD and gender distribution of different groups 
are shown in Table I. All HTLV-1 positive patients were diagnosed by HTLV-1 
Table I. The age and sex distribution of three groups
Group Sex (F/M) Age (mean ± SD)
Control1 10/20 38.3±8.01
Carrier2 5/30 37.03±7.96
Patient3 9/5 45.78±11.86
1 Consists of healthy individual blood donors.
2 Self-declared healthy volunteer blood donors newly detected as HTLV-1 seropositive.
3 HTLV-1 positive patients diagnosed and treated as HAM/TSP for several years.
Table II. Characteristics of patients (HTLV-1+ with HAM/TSP)
Patient 
No.
Age
(year) Sex
Detection time
(year) Medications
 1 29 F 3 α-Interferon, Sodium valproate, Corticosteroid
 2 30 F 5 Calcium
 3 30 F 15 ND
 4 37 M ND ND
 5 40 F ND ND
 6 42 F 1 α-Interferon, Sodium valproate, Corticosteroid
 7 44 F 13 Pregabalin, vitamin B1
 8 45 M ND ND
 9 52 M 20 α-Interferon, Sodium valproate, Corticosteroid, 
Folic acid, Baclofen, Tizanidine
10 52 M ND α-Interferon
11 58 F ND α-Interferon
12 58 M 2 α-Interferon, Corticosteroid
13 65 F 4 Calcium
14 59 F 8 Gabapentin, vitamin E
ND = not defi ned.
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antibody ELISA test and were confi rmed with western blot analysis. The general 
characteristics of the patients are described in Table II.
The control group included 30 healthy blood donors. Controls were con-
fi rmed to be seronegative for HTLV-1, HIV and viral Hepatitis. In addition, they 
fi lled a questionnaire to reveal any diagnosed infl amatory or other potentially 
effi cacious pathologic condition. Healthy and carrier samples were prepared in 
Blood Transfusion Organization of Mashhad. Patient samples were obtained 
from HTLV-1 clinic of neurology department at Ghaem university hospital in 
Mashhad. Written informed consent from all participants was obtained.
ST2 measurement
sST2 was measured with Quantikine Human ELISA kit (R&D Systems) 
according to manufacturer’s instructions. This assay employs the quantitative 
sandwich enzyme immunoassay technique. Samples were diluted 20-fold for 
 assay and the optical density was measured at 450 nm.
Statistical analysis
Statistical analysis was performed with SPSS11.5 software. Each result was 
expressed as mean and standard deviation. Normal distribution of variable was 
assessed by Kolmogorov–Smirnov test. Independent samples t-test and ANOVA 
were used and a two-tailed P value of <0.05 was considered statistically signifi -
cant in all calculations.
Ethical approval
All samples were collected in accordance with the Helsinki declaration on 
human research. The study was reviewed and approved by the ethic committee in 
vice president of research of Mashhad University of Medical Science (MUMS), 
Mashhad, Iran.
Results
The mean age and gender distribution of healthy controls and HTLV-1 se-
ropositive group were matched and no signifi cant difference was observed (p = 
0.84 and 0.06, respectively). Kolmogorov–Smirnov test showed that sST2 distri-
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bution is normal in control, carrier and symptomatic study groups (p = 0.289, 
0.872, 0.995, respectively). Table III shows the mean ± SD of sST2 in different 
study groups. Statistically no signifi cant diffrence between sST2 levels of con-
trols, carriers and HAM/TSP patients was observed (Anova test, p = 0.384). 
Moreover, as shown in Figure 1 although an slightly increased sST2 levels in 
sreopositive groups was observed comparing to healthy controls, such sST2 ele-
vation did not cause signifi cant difference between these groups (t-test, p = 0.91).
We also observed lower levels of serum sST2 in healthy females compared 
to males (t-test, p = 0.02) a fi nding consisting with previous reports [24, 25]. 
Table III. Level of sST2 (mean ± S.D) in HTLV-1+ and control groups. 
Levels are expressed in ng/ml
Control
(N = 30)
HTLV-1+
(N = 49)
Asymptomatic
(N = 35)
Symptomatic
(N = 14)
Male  9.62 ± 4.69 10.25 ± 3.62 10.83 ± 2.72
Female 6.6 ± 2.01  8.04 ± 0.81  8.70 ± 3.91
Figure 1. Serum levels of soluble ST2 in HTLV-1 seropositive group (gray box) 
and healthy controls. Box plots demonstrating gender specifi c distributions of ST2 plasma 
consentrations in 24 male and 55 female individuals
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Similarly, a signifi cant difference between the two genders in seropositive carrier 
group was observed (t-test, p = 0.006). Such difference was also observed when 
total female measurements were compared to total male values (t-test, p = 0.003). 
To exclude the factor of gender, ST2 levels of control and seropositive group were 
compared in each sex. As shown in Figure 1, increased values were observed 
in male seropositive cases compared to healthy men, although the difference was 
not statistically signifi cant (t-test, p = 0.52), a similar fi nding was observed in 
females (t-test, p = 0.11). The serum sST2 levels in asymptomatic carriers were 
comparable with those in symptomatic HAM/TSP patients. Likewise, serum 
level of ST2 in HAM/TSP patients did not show any relation with the duration of 
symptoms (p = 0.565).
Discussion
In this study we investigated sST2 levels in HTLV-1 infected individuals, 
the study was performed in north east of Iran where HTLV-1 is endemic [26, 27]. 
The fi ndings showed an increase trend in chronic HTLV-1 infected individuals 
compared to healthy controls although the difference was not statistically signifi -
cant. Still the results should be treated and interperated with caution. Given the 
high normal variation of sST2 levels in the serum a larger sample size might re-
veal a signifi cant difference.
The participants of the present study had no history of other known in-
fl amatory conditions or cardiac diseases [28] which might affect their sST2 
 levels. Previous studies indicate that sST2 level is not signifi cantly infl uenced by 
age [24], nevertheless in our study the groups were matched according to their 
age. On the other hand, gender has a signifi cant effect on serum sST2 levels. Dif-
ferent studies have generally report lower sST2 levels in females [24]. Concern-
ing the effect of gender, various groups were compared on the basis of sex to 
control this confounding factor, yet, no signifi cant differences were observed.
As mentioned before, high levels of a number of cytokines have been ob-
served in HAM/TSP patients [5–7]. Therefore it seems reasonable to assume that 
other kinds of cytokines might also contribute in the development of HAM/TSP. 
In the present study we underscored sST2 production during HTLV-1 infection. 
However the presented data should be treated as an original idea to propose up-
coming studies.
There are several limitations to our study. First, it is limited by a relatively 
small number of patients. We did not simultaneously measure levels of IL-33 and 
thus cannot comment on the IL-33/sST2 ratio, which might offer additional 
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mechanistic insights. The other important limitation of the study, like many other 
patient-based studies is lack of information on some potential confounding fac-
tors. However, we considered some major confounders and addressed them by a 
researcher-made questionarie, and it is unlikely that confounding from minor 
remained underlying factors have greatly affected the results.
To conclude within our study groups, sST2 levels were slightly higher in 
infected individuals, although such preliminary interpretation merits further 
confi rmatory studies with preferably a higher sample size to assess the patho-
logic role and clinical relevance of sST2. Such studies should be particularly de-
signed in accordance with disease progression to assess any potential predictive 
value of sST2 for development of HTLV-1 associated myelopathy.
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